🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. Apatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. Apatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer Metastatic

    phase 2 small molecule active

    1 trial

  3. Apatinib mesylate tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  4. Apexelsin 5 mg/ml powder for dispersion for infusion., FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, OXALIPLATINE KABI 5 mg/ml, solution à diluer pour perfusion., GEMCITABINE HIKMA 38 mg/ml, solution à diluer pour perfusion, FLUOROURACILE TEVA 5000 mg/100 ml, solution à diluer pour perfusion, IRINOTECAN MEDAC 20 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Resectable borderline pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  5. Aprepitant

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 2 small molecule completed

    2 trials

  6. Aranesp 10 micrograms solution for injection in pre-filled syringe, Saline: a solution of sterile normal saline containing 9.0 grams of sodium chloride (NaCl, table salt) per liter (0.90%).

    Disc Medicine

    Perinatal Arterial Ischemic Stroke (PAIS)

    phase 2 small molecule active

    1 trial

  7. Arbaclofen Placarbil

    Indivior Pty Ltd

    Alcohol Use Disorder

    phase 2 small molecule completed

    1 trial

  8. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial

  9. Armodafinil

    Teva Pharma GmbH

    Bipolar I Depression

    phase 2 small molecule completed

    1 trial

  10. Arsenic Trioxide

    Teva Pharma GmbH

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  11. Arvisol placebo, Arvisol 150mg

    Pari Pharma GmbH

    Patients with severe Alcohol Use Disorder (according to DSM 5) at entry of a scheduled inpatient alcohol cessation attempt

    phase 2 small molecule active

    1 trial

  12. Asciminib, ASCIMINIB HYDROCHLORIDE

    Novartis Pharmaceuticals

    Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation

    phase 2 small molecule active

    1 trial

  13. Asparaginase Erwinia chrysanthemi

    Jazz Pharmaceuticals Ireland Limited

    B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

    phase 2 small molecule active

    1 trial

  14. Atacicept

    Vera Therapeutics

    IgA Nephropathy (IgAN); Berger Disease; Renal and Urinary Disorders

    phase 2 small molecule active

    1 trial

  15. Atezolizumab

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  16. Atezolizumab

    Arcus Biosciences

    Prostate Adenocarcinoma

    phase 2 small molecule active

    1 trial

  17. Atezolizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. Atomoxetin STADA 40 mg Hartkapseln, GELATIN

    Pari Pharma GmbH

    Healthy subjects with no neurological or psychiatric disorders

    phase 2 small molecule active

    1 trial

  19. Atomoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

  20. Atomoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 2 small molecule completed

    1 trial

  21. Atorvastatina Teva Italia 80 mg compresse rivestite con film, Film-coated tablets, white, shaped elliptical, and coated with smooth film. The dimensions of each tablet are approximately 18.8 mm x 10.3 mm (identical to those containing atorvastatin).

    Cardiol Therapeutics

    Arrhythmogenic Cardiomyopathy (ACM)

    phase 2 small molecule active

    1 trial

  22. Atuliflapon, SALBUTAMOL, Placebo to Atuliflapon

    AstraZeneca AB

    Moderate-to-Severe Uncontrolled Asthma

    phase 2 small molecule active

    1 trial

  23. Aumolertinib Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer Stage IV

    phase 2 small molecule active

    1 trial

  24. Autobiographical Memory Flexibility (MemFlex) training

    COGNITION THERAPEUTICS INC

    Major Depressive Disorder

    phase 2 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources